Cochlear Future Growth
Future criteria checks 3/6
Cochlear se prevé un crecimiento anual de los beneficios y los ingresos de 12.3% y 8.4% respectivamente. Se prevé que el BPA sea de grow en 12.4% al año. Se prevé que la rentabilidad de los fondos propios sea de 23.4% en 3 años.
Key information
12.0%
Earnings growth rate
12.0%
EPS growth rate
Medical Equipment earnings growth | 16.2% |
Revenue growth rate | 8.6% |
Future return on equity | 24.5% |
Analyst coverage | Good |
Last updated | 05 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
6/30/2026 | 2,703 | 501 | 486 | 574 | 16 |
6/30/2025 | 2,496 | 443 | 417 | 505 | 17 |
6/30/2024 | 2,276 | 392 | 337 | 440 | 17 |
12/31/2023 | 2,149 | 350 | 335 | 430 | N/A |
9/30/2023 | 2,043 | 326 | 301 | 396 | N/A |
6/30/2023 | 1,936 | 301 | 267 | 362 | N/A |
3/31/2023 | 1,824 | 281 | 263 | 352 | N/A |
12/31/2022 | 1,713 | 261 | 259 | 341 | N/A |
9/30/2022 | 1,681 | 275 | 279 | 359 | N/A |
6/30/2022 | 1,648 | 289 | 299 | 377 | N/A |
3/31/2022 | 1,612 | 273 | 266 | 340 | N/A |
12/31/2021 | 1,575 | 257 | 233 | 304 | N/A |
9/30/2021 | 1,536 | 291 | 216 | 285 | N/A |
6/30/2021 | 1,498 | 324 | 199 | 265 | N/A |
3/31/2021 | 1,403 | 82 | -52 | 34 | N/A |
12/31/2020 | 1,308 | -160 | -302 | -198 | N/A |
9/30/2020 | 1,314 | -199 | -295 | -178 | N/A |
6/30/2020 | 1,321 | -238 | -288 | -158 | N/A |
3/31/2020 | 1,400 | 34 | -80 | 50 | N/A |
12/31/2019 | 1,479 | 306 | 128 | 259 | N/A |
9/30/2019 | 1,453 | 291 | 155 | 277 | N/A |
6/30/2019 | 1,427 | 277 | 181 | 296 | N/A |
3/31/2019 | 1,422 | 270 | 217 | 313 | N/A |
12/31/2018 | 1,418 | 264 | 252 | 330 | N/A |
9/30/2018 | 1,391 | 255 | 230 | 294 | N/A |
6/30/2018 | 1,364 | 246 | 208 | 258 | N/A |
3/31/2018 | 1,329 | 234 | 194 | 254 | N/A |
12/31/2017 | 1,294 | 223 | 180 | 250 | N/A |
9/30/2017 | 1,274 | 223 | N/A | 255 | N/A |
6/30/2017 | 1,254 | 224 | N/A | 260 | N/A |
3/31/2017 | 1,218 | 215 | N/A | 237 | N/A |
12/31/2016 | 1,182 | 206 | N/A | 214 | N/A |
9/30/2016 | 1,156 | 198 | N/A | 199 | N/A |
6/30/2016 | 1,131 | 189 | N/A | 185 | N/A |
3/31/2016 | 1,088 | 179 | N/A | 179 | N/A |
12/31/2015 | 1,045 | 168 | N/A | 172 | N/A |
9/30/2015 | 986 | 157 | N/A | 181 | N/A |
6/30/2015 | 926 | 146 | N/A | 189 | N/A |
3/31/2015 | 899 | 145 | N/A | 178 | N/A |
12/31/2014 | 872 | 144 | N/A | 168 | N/A |
9/30/2014 | 839 | 119 | N/A | 140 | N/A |
6/30/2014 | 805 | 94 | N/A | 111 | N/A |
3/31/2014 | 769 | 85 | N/A | 93 | N/A |
12/31/2013 | 732 | 76 | N/A | 75 | N/A |
9/30/2013 | 742 | 104 | N/A | 72 | N/A |
6/30/2013 | 753 | 133 | N/A | 70 | N/A |
Analyst Future Growth Forecasts
Ingresos vs. tasa de ahorro: CHEO.Y(11.7% al año) es superior a la tasa de ahorro (2.3%).
Beneficios frente mercado: CHEO.YSe prevé que los beneficios de la empresa (12.5% al año) crezcan menos que el mercado US (14.9% al año).
Beneficios de alto crecimiento: CHEO.YSe prevé que los beneficios de la empresa crezcan, pero no significativamente.
Ingresos vs. Mercado: CHEO.YSe prevé que los ingresos de la empresa (8.5% al año) crezcan más deprisa que los del mercado US (8.2% al año).
Ingresos de alto crecimiento: CHEO.YSe prevé que los ingresos de la empresa (8.4% al año) crezcan más despacio que 20% al año.
Earnings per Share Growth Forecasts
Future Return on Equity
Futura rentabilidad financiera (ROE): CHEO.Yse prevé que la Rentabilidad de los fondos propios sea alta dentro de 3 años (23.4%)